Sponsor:
Seagen, a wholly owned subsidiary of Pfizer
Code:
NCT04389632
Conditions
Carcinoma, Non-Small Cell Lung
Squamous Cell Carcinoma of Head and Neck
HER2 Negative Breast Neoplasms
Esophageal Squamous Cell Carcinoma
Esophageal Adenocarcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
sigvotatug vedotin
pembrolizumab
cisplatin
carboplatin
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-14. This information was provided to ClinicalTrials.gov by Seagen, a wholly owned subsidiary of Pfizer on 2025-09-12.